1383481-11-5

Basic information

• Product Name: 7-chloroiMidazo[1,2-b]pyridazine
• Synonyms: 7-chloroiMidazo[1,2-b]pyridazine
• CAS NO: 1383481-11-5
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.56906
• Mol File: 1383481-11-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.71±0.30(Predicted)
• CAS DataBase Reference: 7-chloroiMidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloroiMidazo[1,2-b]pyridazine(1383481-11-5)
• EPA Substance Registry System: 7-chloroiMidazo[1,2-b]pyridazine(1383481-11-5)

Safety Data

• Hazardous Substances Data: 1383481-11-5(Hazardous Substances Data)

Usage

General Description

7-ChloroiMidazo[1,2-b]pyridazine, also known as CIPD, is a chemical compound with the molecular formula C7H5ClN4. It is a white to off-white crystalline powder that is primarily used in the pharmaceutical industry as an intermediate for the synthesis of various drugs. CIPD is known for its potential as an antifungal agent and has been studied for its potential use in the treatment of fungal infections. It is also being investigated for its potential use in the treatment of cancer and other diseases. CIPD is considered to have low toxicity and is generally considered safe for use in pharmaceutical applications. However, as with any chemical, proper handling and safety precautions should be taken when working with CIPD.

Upstream product

• 107-20-0 2-chloroethanal 
• 1314978-36-3 5-chloropyridazin-3-amine 

Downstream Products

• 1383481-21-7 N-[3-(7-{1-[3-(cyanomethyl)azetidin-3-yl]-1H-pyrazol-4-yl}imidazo[1,2-b]pyridazin-3-yl)phenyl]-N'-(2,2,2-trifluoroethyl)urea 
• 1383480-69-0 N-[3-(7-{1-[1-(Cyanoacetyl)-3-(cyanomethyl)azetidin-3-yl]-1H-pyrazol-4-yl]imidazo[1,2-b]pyridazin-3-yl)phenyl]-N'-(2,2,2-trifluoroethyl)urea 
• 1383480-75-8 N-[3-(7-{1-[3-(Cyanomethyl)-1-(cyclopropylmethyl)azetidin-3-yl]-1H-pyrazol-4-yl}imidazo[1,2-b]pyridazin-3-yl)phenyl]-N'-(2,2,2-trifluoroethyl)urea 
• 1383480-76-9 3-(Cyanomethyl)-N-phenyl-3-(4-{3-[3-({[(2,2,2-trifluoroethyl)amino]carbonyl}amino)phenyl]imidazo[1,2-b]pyridazin-7-yl}-1H-pyrazol-1-yl)azetidine-1-carboxamide 
• 1383480-77-0 N-[3-(7-{1-[3-(Cyanomethyl)-1-(morpholin-4-ylcarbonyl)azetidin-3-yl]-1H-pyrazol-4-yl}imidazo[1,2-b]pyridazin-3-yl)phenyl]N'-(2,2,2-trifluoroethyl)urea 
• 1383480-79-2 3-(Cyanomethyl)-N-(cyclopropylmethyl)-3-(4-{3-[3-({[(2,2,2-trifluoroethyl)amino]carbonyl}amino)phenyl]imidazo[1,2-b]pyridazin-7-yl}-1H-pyrazol-1-yl)azetidine-1-carboxamide 
• 1383480-80-5 Cyclopropylmethyl 3-(cyanomethyl)-3-(4-{3-[3-({[(2,2,2-trifluoroethyl)amino]carbonyl]amino)phenyl]imidazo[1,2-b]pyridazin-7-yl}-1H-pyrazol-1-yl)azetidine-1-carboxylate 
• 1383480-65-6 N-{3-[7-(1-{3-(Cyanomethyl)-1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]azetidin-3-yl}-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]phenyl}-N'-(2,2,2-trifluoroethyl)urea 
• 1383481-13-7 7-chloro-3-iodoimidazo[1,2-b]pyridazine 
• 1235545-87-5 3-bromo-7-chloroimidazo[1,2-b]pyridazine 
• 1383481-22-8 N-{3-[7-(1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]phenyl}-N'-(2,2,2-trifluoroethyl)urea 
• 1383480-81-6 N-(3-{7-[1-(2-cyano-1-methylethyl)-1H-pyrazol-4-yl]imidazo[1,2-b]pyridazin-3-yl}phenyl)-N'-(2,2,2-trifluoroethyl)urea 
• 1383481-20-6 tert-butyl 3-(cyanomethyl)-3-(4-{3-[3-({[(2,2,2-trifluoroethyl)amino]carbonyl}amino)phenyl]imidazo[1,2-b]pyridazin-7-yl}-1H-pyrazol-1-yl)azetidine-1-carboxylate 
• 1383480-46-3 N-cyclopropyl-2-(4-{3-[3-({[(2,2,2-trifluoroethyl)amino]carbonyl}amino)phenyl]imidazo[1,2-b]pyridazin-7-yl}-1H-pyrazol-1-yl)propanamide 

Relevant articles and documents

SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF

Provided are a substituted fused aromatic ring derivative, a composition containing the compound, and a use thereof. The substituted fused aromatic ring derivative is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition can be used to treat various protein tyrosine kinase-mediated diseases or disorders.

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.